Neuphoria Therapeutics Inc. (NEUP)
Nasdaq: NEUP · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2002
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in June.| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period ending | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Report filed | Sep 18, 2026 | Sep 29, 2025 | Sep 30, 2024 | Oct 18, 2023 | Oct 14, 2022 |
| Revenue | 1,174,165 | 15,649,448 | · | · | · |
| Research and development | · | 9,005,097 | 9,417,785 | 13,071,705 | · |
| General and administrative | 7,439,224 | 7,773,442 | 8,474,591 | 8,911,271 | · |
| Total operating expenses | 17,625,231 | 16,778,539 | 17,892,376 | 21,982,976 | · |
| Operating income | -16,451,066 | -1,129,091 | -17,892,376 | -21,982,976 | · |
| Interest and investment income | 665,571 | 166,498 | 220,097 | 323,158 | · |
| Total non-operating income (expense) | 2,859,962 | 291,093 | 2,312,890 | 462,125 | · |
| Income before income taxes | -13,591,104 | -837,998 | -15,579,486 | -21,520,851 | · |
| Income tax expense | -139,173 | -468,366 | -87,320 | -139,174 | · |
| Net income | -13,451,931 | -369,632 | -15,492,166 | -21,381,677 | · |
| Earnings per share, basic | -3.06 | -0.23 | -18.62r | -43.20b | · |
| Earnings per share, diluted | -3.06 | -0.23 | -18.62r | -43.20b | · |
| Weighted average shares, basic | 4,395,776 | 1,622,924 | 832,225r | 679,970b | · |
| Weighted average shares, diluted | 4,395,776 | 1,622,924 | 832,225r | 679,970b | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-2160 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding